Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting urinary side effects after receiving radiation therapy.  The test, called PROSTOX, is the first of its kind to use microRNAs to predict toxicity from cancer therapy. It could help prevent the burden of long-term complications by identifying patients most at risk before treatment even begins. In a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, the UCLA team validated PROSTOX’s ability to predict long-term urinary side effects, which can include urinary tract pain, blood in the urine, increased frequency of urination, and urinary urgency or leakage. The researchers also found that different genetic factors are linked to different types of side effects, reinforcing the need for more personalized… 

Burlington, N.C., 7. April 2025 – Labcorp (NYSE: LH), ein weltweit führendes Unternehmen im Bereich innovativer Labordienstleistungen, hat heute die landesweite Einführung eines neuartigen Bluttests angekündigt, der die Diagnose von Alzheimer beschleunigen soll. Der sogenannte pTau-217/Beta-Amyloid-42-Ratio-Test ist der erste seiner Art und nutzt eine Immunoassay-Technologie, um zwei wichtige Biomarker der Alzheimer-Krankheit im Blut zu messen. Dieser Test markiert einen bedeutenden Fortschritt in der Diagnostik neurodegenerativer Erkrankungen. Er ermöglicht es Ärzten, die Anwesenheit von Amyloid-Pathologien, die mit Alzheimer in Verbindung stehen, schneller und präziser zu bestätigen. In Kombination mit klinischen Befunden soll der Test den Weg zu einer frühzeitigen Diagnose ebnen – ein entscheidender Faktor für Patienten, die an kognitiven Beeinträchtigungen leiden. „Mit diesem Test erweitern wir unser führendes Angebot an blutbasierten Diagnoselösungen und unterstützen Ärzte und Patienten dabei, fundierte Entscheidungen zu treffen“, erklärte ein Sprecher von Labcorp. Die Einführung erfolgte… 

The Conference Board Employment Trends Index™ (ETI) increased in March to 109.03, from a downwardly revised 108.47 in February. The Employment Trends Index is a leading composite index for payroll employment. When the Index increases, employment is likely to grow as well, and vice versa. Turning points in the Index indicate that a change in the trend of job gains or losses is about to occur in the coming months. Initial claims for unemployment insurance (an ETI component) declined in March following February’s increase, driven by federal and private-sector layoff announcements. The share of involuntary part-time workers declined to 17.4%, after reaching 18% in February—its highest level since 2021. The share of consumers who report ‚jobs are hard to get’—an ETI component from the Consumer Confidence Survey®—fell slightly in March to 15.7% after also peaking at a five-month high in…